期刊文献+

EZH2基因在他莫昔芬耐药乳腺癌MCF-7细胞系的表达及其对细胞增殖的影响 被引量:1

Expression of EZH2 gene in tamoxifen-resistant breast cancer MCF-7 cells and its influence on cell proliferation
原文传递
导出
摘要 目的检测EZH2基因在他莫昔芬耐药乳腺癌MCF-7细胞(MCF-7/Tam+细胞)及他莫昔芬敏感乳腺癌MCF-7细胞(MCF-7/Tam-细胞)的表达,并探讨EZH2对两种乳腺癌细胞系增殖的影响。方法首先通过Western blot法在MCF-7/Tam+细胞和MCF-7/Tam-细胞中检测EZH2蛋白表达差异,并采用10 nmol/L的雌二醇和10 nmol/L 4-羟他莫昔芬(4-OHT)分别处理MCF-7/Tam-细胞24 h后检测EZH2蛋白的变化。使用LipofectamineTM2000将靶向抑制EZH2的siRNA(siRNA-EZH2)转染至MCF-7/Tam+细胞,运用实时PCR检测EZH2 mRNA的相对表达量,Western blot法检测EZH2蛋白表达量,以验证siRNA的有效性。最后将siRNA-EZH2转染至MCF-7/Tam-和MCF-7/Tam+细胞,采用细胞计数检测细胞数,用MTT法检测细胞增殖情况(570 nm波长处吸光度值)。计量资料用x珋±s表示,两组均数比较用t检验,细胞计数比较采用重复测量的方差分析。结果 EZH2蛋白在MCF-7/Tam+细胞中相对表达量为2.237±0.091,高于在MCF-7/Tam-细胞中的相对表达量(1.870±0.114)(t=8.582,P=0.013)。经10 nmol/L的雌二醇诱导MCF-7/Tam-细胞24 h后EZH2蛋白相对表达量为0.657±0.015,阴性对照组EZH2相对表达量为0.480±0.017,而相同浓度的4-羟基他莫昔芬处理MCF-7/Tam-细胞24 h后EZH2蛋白相对表达量为0.423±0.012,雌二醇+他莫昔芬处理组为0.483±0.006,4组差异有统计学意义(F=175.032,P=0.000)。将siRNA-EZH2转染至MCF-7/Tam+细胞后,转染siRNA-EZH2组与空质粒转染组(siRNA-Control组)EZH2 mRNA相对表达量分别为0.310±0.062、1.007±0.136,差异有统计学意义(t=14.061,P=0.005);转染siRNA-EZH2组与siRNA-Control组EZH2蛋白的相对表达量分别为3.783±0.045、6.500±0.327,差异有统计学意义(t=15.366,P=0.004)。细胞计数结果显示,转染siRNA-EZH2的MCF-7/Tam-细胞组(Tam-EZH2组)的细胞数(单位:1×105)在第3、4、5天分别为7.540±0.790、10.243±1.360、14.270±1.992,Tam-Control组细胞数在第3、4、5天分别为12.113±1.666、17.853±1.900、25.670±2.318,组间� Objective To investigate the expression of EZH2 gene in tamoxifen-resistant breast cancer MCF-7 cells (MCF-7/Tam+) and tamoxifen-sensitive breast cancer MCF-7 cells( MCF-7/Tam-), and explore the effects of EZH2 on the proliferation of the two breast cancer cell lines. Methods Firstly, the expressions of EZH2 in MCF-7/Tam+ and MCF-7/Tam- cells were detected by Western blot. After MCF-7/Tam- cells being treated by 10 nmol/1 estradiol and 10 nmol/1 4-hydroxy tamoxifen(4-OHT) for 24 h, the expression of EZH2 protein was detected by Western blot. siRNA with targeted inhibition of EZH2 (siRNA-EZH2) was transfected into MCF-7/Tam+ using LipofectamineTM 2000. The real-time PCR and Western blot were used to detect the mRNA and protein expression of EZH2 respectively in order to confirm the validity of siRNA. Finally, siRNA-EZH2 was transfected into MCF-7/Tam- and MCF-7/Tam+ ceils. Cell count assay was used to measure the cell number and MTT to detect the cell proliferation ( optical density at 570 nm wavelength). Measurement data were expressed as x^-±s, and t test was used to compare the means. The cell count data were compared by repeated measurement analysis of variance. Results The relative expression of EZH2 protein in MCF-7/Tam+ was 2. 237 ±0. 091, significantly higher than 1. 870 ±0. 114 in MCF-7/Tam- ( t = 8. 582, P = 0. 013 ). The relative expression of EZH2 protein was 0. 657±0.015 in MCF-7/Tam- cells after being treated by 10 nmol/L estradiol for 24 h,0. 480±0. 017 in negative control, and 0.423 ±0. 012 in MCF-7/Tam- cells after being treated by 10 nmol/L 4-OHT for 24 h,0. 483±0.006 in MCF-7/Tam-cells treated by estradiol+4-OHT, the difference was statistically significant( F= 175. 032, P = 0. 000). After transfecting siRNA-EZH2 into MCF-7/ Tam+ cells,the relative expression of EZH2 mRNA in siRNA-EZH2 group and siRNA-control group were 0. 310± 0.062 and 1. 007 ±0. 136, the difference was statistically significant ( t = 14. 061, P = 0. 005 ) ; the relative e
出处 《中华乳腺病杂志(电子版)》 CAS CSCD 2015年第1期21-26,共6页 Chinese Journal of Breast Disease(Electronic Edition)
基金 安徽省自然科学基金资助项目(11040606M180)
关键词 乳腺肿瘤 他莫昔芬 RNA 小分子干扰 MCF-7细胞 EZH2 Breast neoplasms Tamoxifen RNA, small interfering MCF-7 cells EZH2
  • 相关文献

参考文献1

二级参考文献46

  • 1Esteller M. Epigenetics in cancer [J]. N Engl J Med, 2008,358 (11):1148-1159. 被引量:1
  • 2Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis [J]. Cell Mol Life Sci, 2011,68(10):1681-1702. 被引量:1
  • 3Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs [J]. Annu Rev Pharmacol Toxicol, 2009,49: 243-263. 被引量:1
  • 4Ferreri A J, Deli'Oro S, CapellO U, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas [J]. Br J Haematol, 2004,126(5):657-664. 被引量:1
  • 5Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias [J]. Blood, 1998, 92( 11 ):4296-4307. 被引量:1
  • 6Strathdee G, MacKean M J, Illand M, et al, A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer [J]. Oncogene, 1999,18(14):2335-2341. 被引量:1
  • 7Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer [J]. J Clin Oncol, "1984,2(10): 1102-1109. 被引量:1
  • 8Berger SL. The complex language of chromatin regulation during transcription [J]. Nature, 2007,447(7143):407-412. 被引量:1
  • 9Chi P, Allis CD, Wang GG. Covalent histone modifications miswritten, misinterpreted and mis-erased in human cancers [J]. Nat Rev Cancer, 2010,10(7):457-469. 被引量:1
  • 10Portela A, Esteller M. Epigenetic modifications and human disease [J]. Nat BiotechnoJ, 2010,28(10):1057-1068. 被引量:1

共引文献5

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部